Abstract
Tumor necrosis factor receptor-associated periodic syndrome (TRAPS), formerly known as familial Hibernian fever, is the most common autosomal dominant autoinflammatory disease, resulting from mutations in the TNFRSF1A gene, encoding the 55-kD tumor necrosis factor receptor. The pathophysiologic mechanism of TRAPS remains ambiguous and only partially explained. The onset age of the syndrome is variable and the clinical scenery is characterized by recurrent episodes of high-grade fever that typically lasts 1–3 weeks, associated with migrating myalgia, pseudocellulitis, diffuse abdominal pain, appendicitis-like findings, ocular inflammatory signs, and risk of long-term amyloidosis. Fever episodes are responsive to high-dose corticosteroids, but different classes of drugs have been reported to be ineffective. The use of etanercept is unable to control systemic inflammation, while interleukin-1 blockade has been shown as effective in the control of disease activity in many patients reported so far.
Similar content being viewed by others
References
Touitou I, Koné-Paut I (2008) Autoinflammatory diseases. Best Pract Res Clin Rheumatol 22:811–829
McGonagle D, McDermott MF (2006) A proposed classification of the immunological diseases. PLoS Med 3:e297
Drenth JP, van der Meer JW (2006) The inflammasome—a linebacker of innate defense. N Engl J Med 355:730–732
Rigante D (2012) The fresco of autoinflammatory diseases from the pediatric perspective. Autoimmun Rev 11:348–356
Gattorno M, Federici S, Pelagatti MA, Caorsi R, Brisca G, Malattia C et al (2008) Diagnosis and management of autoinflammatory diseases in childhood. J Clin Immunol 28(Suppl 1):S73–S83
Rigante D (2009) Autoinflammatory syndromes behind the scenes of recurrent fevers in children. Med Sci Monit 15:RA179–RA187
Williamson LM, Hull D, Mehta R, Reeves WG, Robinson BH, Toghill PJ (1982) Familial Hibernian fever. Q J Med 51:469–480
McDermott MF, Aksentijevich I, Galon J, McDermott EM, Ogunkolade BW, Centola M et al (1999) Germline mutations in the extracellular domains of the 55 kDa TNF receptor, TNFR1, define a family of dominantly inherited autoinflammatory syndromes. Cell 97:133–144
Aganna E, Hammond L, Hawkins PN, Aldea A, McKee SA, van Amstel HK et al (2003) Heterogeneity among patients with tumor necrosis factor receptor-associated periodic syndrome phenotypes. Arthritis Rheum 48:2632–2644
Aksentijevich I, Galon J, Soares M, Mansfield E, Hull K, Oh HH et al (2001) The tumor-necrosis-factor receptor-associated periodic syndrome: new mutations in TNFRSF1A, ancestral origins, genotype-phenotype studies, and evidence for further genetic heterogeneity of periodic fevers. Am J Hum Genet 69:301–314
Cantarini L, Lucherini OM, Cimaz R, Brizi MG, Galeazzi M (2010) Serosal involvement in adult-onset autoinflammatory disorders. Respiration 80:260–261
Cantarini L, Lucherini OM, Brucato A, Barone L, Cumetti D, Iacoponi F et al (2012) Clues to detect tumor necrosis factor receptor-associated periodic syndrome (TRAPS) among patients with idiopathic recurrent acute pericarditis: results of a multicentre study. Clin Res Cardiol 101:525–531
Cantarini L, Lucherini OM, Baldari CT, Laghi Pasini F, Galeazzi M (2010) Familial clustering of recurrent pericarditis may disclose tumour necrosis factor receptor-associated periodic syndrome. Clin Exp Rheumatol 28:405–407
Cantarini L, Lucherini OM, Cimaz R, Baldari CT, Bellisai F, Rossi Paccani S et al (2009) Idiopathic recurrent pericarditis refractory to colchicine treatment can reveal tumor necrosis factor receptor-associated periodic syndrome. Int J Immunopathol Pharmacol 22:1051–1058
Cantarini L, Lucherini OM, Cimaz R, Baldari CT, Laghi Pasini F, Galeazzi M (2010) Sacroileitis and pericarditis: atypical presentation of tumor necrosis factor receptor-associated periodic syndrome and response to etanercept therapy. Clin Exp Rheumatol 28:290–291
Lainka E, Neudorf U, Lohse P, Timmann C, Stojanov S, Huss K et al (2009) Incidence of TNFRSF1A mutations in German children: epidemiological, clinical and genetic characteristics. Rheumatology (Oxford) 48:987–991
Hull KM, Drewe E, Aksentijevich I, Singh HK, Wong K, McDermott EM et al (2002) The TNF receptor-associated periodic syndrome (TRAPS): emerging concepts of an autoinflammatory disorder. Medicine (Baltimore) 81:349–368
Kusuhara K, Nomura A, Nakao F, Hara T (2004) Tumour necrosis factor receptor-associated periodic syndrome with a novel mutation in the TNFRSF1A gene in a Japanese family. Eur J Pediatr 163:30–32
McDermott MF, Ogunkolade BW, McDermott EM, Jones LC, Wan Y, Quane KA et al (1998) Linkage of familial Hibernian fever to chromosome 12p13. Am J Hum Genet 62:1446–1451
Mulley J, Saar K, Hewitt G, Ruschendorf F, Phillips H, Colley A et al (1998) Gene localization for an autosomal dominant familial periodic fever to 12p13. Am J Hum Genet 62:884–889
Turner MD, Chaudhry A, Nedjai B (2012) Tumour necrosis factor receptor trafficking dysfunction opens the TRAPS door to pro-inflammatory cytokine secretion. Biosci Rep 32:105–112
Rebelo SL, Bainbridge SE, Amel-Kashipaz MR, Radford PM, Powell RJ, Todd I et al (2006) Modeling of tumor necrosis factor receptor superfamily 1A mutants associated with tumor necrosis factor receptor-associated periodic syndrome indicates misfolding consistent with abnormal function. Arthritis Rheum 54:2674–2687
Cantarini L, Rigante D, Merlini G, Vitale A, Caso F, Lucherini OM et al (2013) The expanding spectrum of low-penetrance TNFRSF1A gene variants in adults presenting with recurrent inflammatory attacks: clinical manifestations and long-term follow-up. Semin Arthritis Rheum. doi:10.1016/j.semarthrit.2013.12.002
Sarrauste de Menthiere C, Terriere S, Pugnere D, Ruiz M, Demaille J, Touitou I (2003) INFEVERS: the Registry for FMF and hereditary inflammatory disorders mutations. Nucleic Acids Res 31:282–285
Lobito AA, Gabriel TL, Medema JP, Kimberley FC (2011) Disease causing mutations in the TNF and TNFR superfamilies: focus on molecular mechanisms driving disease. Trends Mol Med 17:494–505
Bazzoni F, Beutler B (1996) The tumor necrosis factor ligand and receptor families. N Engl J Med 334:1717–1725
Gommerman JL, Browning JL (2003) Lymphotoxin/light, lymphoid microenvironments and autoimmune disease. Nat Rev Immunol 3:642–655
Schottelius AJ, Moldawer LL, Dinarello CA, Asadullah K, Sterry W, Edwards CK 3rd (2004) Biology of tumor necrosis factor-alpha—implications for psoriasis. Exp Dermatol 13:193–222
Kollias G (2005) TNF pathophysiology in murine models of chronic inflammation and autoimmunity. Semin Arthritis Rheum 34:3–6
Aloisi F, Pujol-Borrell R (2006) Lymphoid neogenesis in chronic inflammatory diseases. Nat Rev Immunol 6:205–217
Brennan FM, Maini RN, Feldmann M (1995) Cytokine expression in chronic inflammatory disease. Br Med Bull 51:368–384
Beutler B, Cerami A (1989) The biology of cachectin/TNF—a primary mediator of the host response. Annu Rev Immunol 7:625–655
Ware CF, Crowe PD, Grayson MH, Androlewicz MJ, Browning JL (1992) Expression of surface lymphotoxin and tumor necrosis factor on activated T, B, and natural killer cells. J Immunol 149:3881–3888
Vassalli P (1992) The pathophysiology of tumor necrosis factors. Annu Rev Immunol 10:411–452
Wajant H, Pfizenmaier K, Scheurich P (2003) Tumor necrosis factor signaling. Cell Death Differ 10:45–65
Kimberley FC, Lobito AA, Siegel RM, Screaton GR (2007) Falling into TRAPS—receptor misfolding in the TNF receptor 1-associated periodic fever syndrome. Arthritis Res Ther 9:217
Banner DW, D'Arcy A, Janes W, Gentz R, Schoenfeld HJ, Broger C et al (1993) Crystal structure of the soluble human 55 kd TNF receptor-human TNF beta complex: implications for TNF receptor activation. Cell 73:431–445
Magnotti F, Vitale A, Rigante D, Lucherini OM, Cimaz R, Muscari I et al (2013) The most recent advances in pathophysiology and management of tumour necrosis factor receptor-associated periodic syndrome (TRAPS): personal experience and literature review. Clin Exp Rheumatol 31:141–149
Lobito AA, Kimberley FC, Muppidi JR, Komarow H, Jackson AJ, Hull KM et al (2006) Abnormal disulfide-linked oligomerization results in ER retention and altered signaling by TNFR1 mutants in TNFR1-associated periodic fever syndrome (TRAPS). Blood 108:1320–1327
Huggins ML, Radford PM, McIntosh RS, Bainbridge SE, Dickinson P, Draper-Morgan KA et al (2004) Shedding of mutant tumor necrosis factor receptor superfamily 1A associated with tumor necrosis factor receptor-associated periodic syndrome: differences between cell types. Arthritis Rheum 50:2651–2659
Kallinich T, Briese S, Roesler J, Rudolph B, Sarioglu N, Blankenstein O et al (2004) Two familial cases with tumor necrosis factor receptor-associated periodic syndrome caused by a non-cysteine mutation (T50M) in the TNFRSF1A gene associated with severe multiorganic amyloidosis. J Rheumatol 31:2519–2522
Stojanov S, Dejaco C, Lohse P, Huss K, Duftner C, Belohradsky BH et al (2008) Clinical and functional characterisation of a novel TNFRSF1A c.605 T > A/V173D cleavage site mutation associated with tumour necrosis factor receptor-associated periodic fever syndrome (TRAPS), cardiovascular complications and excellent response to etanercept treatment. Ann Rheum Dis 67:1292–1298
Park H, Bourla AB, Kastner DL, Colbert RA, Siegel RM (2012) Lighting the fires within: the cell biology of autoinflammatory diseases. Nat Rev Immunol 12:570–580
Simon A, Park H, Maddipati R, Lobito AA, Bulua AC, Jackson AJ et al (2010) Concerted action of wild-type and mutant TNF receptors enhances inflammation in TNF receptor 1-associated periodic fever syndrome. Proc Natl Acad Sci U S A 107:9801–9806
Bulua AC, Simon A, Maddipati R, Pelletier M, Park H, Kim KY et al (2011) Mitochondrial reactive oxygen species promote production of proinflammatory cytokines and are elevated in TNFR1-associated periodic syndrome (TRAPS). J Exp Med 208:519–533
Kamata H, Honda S, Maeda S, Chang L, Hirata H, Karin M (2005) Reactive oxygen species promote TNF alpha-induced death and sustained JNK activation by inhibiting MAP kinase phosphatases. Cell 120:649–661
Dickie LJ, Aziz AM, Savic S, Lucherini OM, Cantarini L, Geiler J et al (2012) Involvement of X-box binding protein 1 and reactive oxygen species pathways in the pathogenesis of tumour necrosis factor receptor-associated periodic syndrome. Ann Rheum Dis 71:2035–2043
Pahl HL, Baeuerle PA (1997) The ER-overload response: activation of NF-kappa B. Trends Biochem Sci 22:63–67
Bernales S, Papa FR, Walter P (2006) Intracellular signaling by the unfolded protein response. Annu Rev Cell Dev Biol 22:487–508
Bachetti T, Chiesa S, Castagnola P, Bani D, Di Zanni E, Omenetti A et al (2013) Autophagy contributes to inflammation in patients with TNFR-associated periodic syndrome (TRAPS). Ann Rheum Dis 72:1044–1052
Ceribelli A, Yao B, Dominguez-Gutierrez PR, Nahid MA, Satoh M, Chan EK (2011) MicroRNAs in systemic rheumatic diseases. Arthritis Res Ther 13:229
Wang GK, Zhu JQ, Zhang JT, Li Q, Li Y, He J et al (2010) Circulating microRNA: a novel potential biomarker for early diagnosis of acute myocardial infarction in humans. Eur Heart J 31:659–666
Lucherini OM, Obici L, Ferracin M, Fulci V, McDermott MF, Merlini G et al (2013) First report of circulating microRNAs in tumour necrosis factor receptor-associated periodic syndrome (TRAPS). PLoS One 8:e73443
Rittore C, Sanchez E, Soler S, Barat-Houari M, Albers M, Obici L et al (2014) Identification of a new exon 2-skipped TNFR1 transcript: regulation by three functional polymorphisms of the TNFR-associated periodic syndrome (TRAPS) gene. Ann Rheum Dis 73:290–297
Cantarini L, Lucherini OM, Iacoponi F, Cimaz R, Simonini G, Rigante D et al (2010) Development and preliminary validation of a diagnostic score for identifying patients affected with adult-onset autoinflammatory disorders. Int J Immunopathol Pharmacol 23:1133–1141
Cantarini L, Vitale A, Lucherini OM, Muscari I, Magnotti F, Brizi G et al (2013) Childhood versus adulthood-onset autoinflammatory disorders: myths and truths intertwined. Reumatismo 65:55–62
Stojanov S, McDermott MF (2005) The tumour necrosis factor receptor-associated periodic syndrome: current concepts. Expert Rev Mol Med 7:1–18
Dodé C, Andre M, Bienvenu T, Hausfater P, Pecheux C, Bienvenu J et al (2002) The enlarging clinical, genetic, and population spectrum of tumor necrosis factor receptor-associated periodic syndrome. Arthritis Rheum 46:2181–2188
Rigante D, Frediani B, Galeazzi M, Cantarini L (2013) From the Mediterranean to the sea of Japan: the transcontinental odyssey of autoinflammatory diseases. Biomed Res Int 2013:485103
Cantarini L, Lucherini OM, Cimaz R, Rigante D, Baldari CT, Laghi Pasini F et al (2012) Typical and severe tumor necrosis factor receptor-associated periodic syndrome in the absence of mutations in the TNFRSF1A gene: a case series. Rheumatol Int 32:4015–4018
Lachmann HJ, Papa R, Gerhold K, Obici L, Touitou I, Cantarini L et al (2013) The phenotype of TNF receptor-associated autoinflammatory syndrome (TRAPS) at presentation: a series of 158 cases from the Eurofever/EUROTRAPS international registry. Ann Rheum Dis. doi:10.1136/annrheumdis-2013-204184
Cantarini L, Lucherini OM, Cimaz R, Galeazzi M (2010) Recurrent pericarditis caused by a rare mutation in the TNFRSF1A gene and with excellent response to anakinra treatment. Clin Exp Rheumatol 28:802
Toro JR, Aksentijevich I, Hull K, Dean J, Kastner DL (2000) Tumor necrosis factor receptor-associated periodic syndrome: a novel syndrome with cutaneous manifestations. Arch Dermatol 136:1487–1494
Rigante D, Cantarini L (2011) Monogenic autoinflammatory syndromes at a dermatological level. Arch Dermatol Res 303:375–380
Schmaltz R, Vogt T, Reichrath J (2010) Skin manifestations in tumor necrosis factor receptor-associated periodic syndrome (TRAPS). Dermatoendocrinol 2:26–29
Hull KM, Wong K, Wood GM, Chu WS, Kastner DL (2002) Monocytic fasciitis: a newly recognized clinical feature of tumor necrosis factor receptor dysfunction. Arthritis Rheum 46:2189–2194
Caso F, Rigante D, Vitale A, Lucherini OM, Costa L, Atteno M et al (2013) Monogenic autoinflammatory syndromes: state of the art on genetic, clinical, and therapeutic issues. Int J Rheumatol. doi:10.1155/2013/513782
Haas SL, Lohse P, Schmitt WH, Hildenbrand R, Karaorman M, Singer MV et al (2006) Severe TNF receptor-associated periodic syndrome due to 2 TNFRSF1A mutations including a new F60V substitution. Gastroenterology 130:172–178
Yao Q, Englund KA, Hayden SP, Tomecki KJ (2012) Tumor necrosis factor receptor associated periodic fever syndrome with photographic evidence of various skin disease and unusual phenotypes: case report and literature review. Semin Arthritis Rheum 41:611–617
Minden K, Aganna E, McDermott MF, Zink A (2004) Tumour necrosis factor receptor associated periodic syndrome (TRAPS) with central nervous system involvement. Ann Rheum Dis 63:1356–1357
Wildemann B, Rudofsky G Jr, Kress B, Jarius S, Konig F, Schwenger V (2007) The tumor-necrosis-factor-associated periodic syndrome, the brain, and tumor-necrosis-factor-alpha antagonists. Neurology 68:1742–1744
Obici L, Merlini G (2012) Amyloidosis in autoinflammatory syndromes. Autoimmun Rev 12:14–17
Rigante D, Capoluongo E (2011) The plodding diagnosis of monogenic autoinflammatory diseases in childhood: from the clinical scenery to laboratory investigation. Clin Chem Lab Med 49:783–791
Pelagatti MA, Meini A, Caorsi R, Cattalini M, Federici S, Zulian F et al (2011) Long-term clinical profile of children with the low-penetrance R92Q mutation of the TNFRSF1A gene. Arthritis Rheum 63:1141–1150
Ravet N, Rouaghe S, Dode C, Bienvenu J, Stirnemann J, Levy P et al (2006) Clinical significance of P46L and R92Q substitutions in the tumour necrosis factor superfamily 1A gene. Ann Rheum Dis 65:1158–1162
Cantarini L, Lucherini OM, Cimaz R, Brizi MG, Galeazzi M (2011) Autoinflammatory disorders and patients with isolated serosal involvement. Rheumatol Int 31:979–980
Cantarini L, Imazio M, Brizi MG, Lucherini OM, Brucato A, Cimaz R et al (2013) Role of autoimmunity and autoinflammation in the pathogenesis of idiopathic recurrent pericarditis. Clin Rev Allergy Immunol 44:6–13
Cantarini L, Lucherini OM, Vitale A, Sabadini L, Brizi MG, Frediani B et al (2013) Expanding spectrum of TNFRSF1A gene mutations among patients with idiopathic recurrent acute pericarditis. Intern Med J 43:725–727
Cantarini L, Imazio M, Brucato A, Lucherini OM, Galeazzi M (2010) Innate versus acquired immune response in the pathogenesis of recurrent idiopathic pericarditis. Autoimmun Rev 9:436–440
Rigante D, Cantarini L, Imazio M, Lucherini OM, Sacco E, Galeazzi M et al (2011) Autoinflammatory diseases and cardiovascular manifestations. Ann Med 43:341–346
Trost S, Rose CD (2005) Myocarditis and sacroiliitis: 2 previously unrecognized manifestations of tumor necrosis factor receptor associated periodic syndrome. J Rheumatol 32:175–177
Roubille F, Cayla G, Gahide G, Mourad G, Macia JC (2009) Acute myocarditis and tumor necrosis factor receptor-associated periodic (TRAP) syndrome: first case described and discussion. Eur J Intern Med 20:e25–e26
Chia S, Qadan M, Newton R, Ludlam CA, Fox KA, Newby DE (2003) Intra-arterial tumor necrosis factor-alpha impairs endotheliumdependent vasodilatation and stimulates local tissue plasminogen activator release in humans. Arterioscler Thromb Vasc Biol 23:695–701
Muscari I, Iacoponi F, Cantarini L, Lucherini OM, Simonini G, Brizi MG et al (2012) The diagnostic evaluation of patients with potential adult-onset autoinflammatory disorders: our experience and review of the literature. Autoimmun Rev 12:10–13
Cantarini L, Iacoponi F, Lucherini OM, Obici L, Brizi MG, Cimaz R et al (2011) Validation of a diagnostic score for the diagnosis of autoinflammatory diseases in adults. Int J Immunopathol Pharmacol 24:695–702
Manukyan G, Ghazaryan K, Ktsoyan Z, Khachatryan Z, Kelly D, Tatyan M et al (2010) Comparative analysis of cytokine profiles in autoinflammatory and autoimmune conditions. Cytokine 50:146–151
Husby G, Husebekk A, Skogen B, Sletten K, Marhaug G, Magnus J et al (1988) Serum amyloid A (SAA)-the precursor of protein AA in secondary amyloidosis. Adv Exp Med Biol 243:185–192
Yang Z, Tao T, Raftery MJ, Youssef P, Di Girolamo N, Geczy CL (2001) Proinflammatory properties of the human S100 protein S100A12. J Leukoc Biol 69:986–994
Cantarini L, Rigante D, Brizi MG, Lucherini OM, Sebastiani GD, Vitale A et al (2012) Clinical and biochemical landmarks in systemic autoinflammatory diseases. Ann Med 44:664–673
Cantarini L, Obici L, Simonini G, Cimaz R, Bacarelli MR, Merlini G et al (2012) Serum leptin, resistin, visfatin and adiponectin levels in tumor necrosis factor receptor-associated periodic syndrome (TRAPS). Clin Exp Rheumatol 30:S108–S114
Cantarini L, Lucherini OM, Muscari I, Frediani B, Galeazzi M, Brizi MG et al (2012) Tumour necrosis factor receptor-associated periodic syndrome (TRAPS): state of the art and future perspectives. Autoimmun Rev 12:38–43
Ter Haar N, Lachmann H, Ozen S, Woo P, Uziel Y, Modesto C et al (2013) Treatment of autoinflammatory diseases: results from the Eurofever Registry and a literature review. Ann Rheum Dis 72:678–685
Cantarini L, Lucherini OM, Galeazzi M, Fanti F, Simonini G, Baldari CT et al (2009) Tumour necrosis factor receptor-associated periodic syndrome caused by a rare mutation in the TNFRSF1A gene, and with excellent response to etanercept treatment. Clin Exp Rheumatol 27:890–891
Cantarini L, Rigante D, Lucherini OM, Cimaz R, Laghi Pasini F, Baldari CT et al (2010) Role of etanercept in the treatment of tumor necrosis factor receptor-associated periodic syndrome: personal experience and review of the literature. Int J Immunopathol Pharmacol 23:701–707
Bulua AC, Mogul DB, Aksentijevich I, Singh H, He DY, Muenz LR et al (2012) Efficacy of etanercept in the tumor necrosis factor receptor-associated periodic syndrome: a prospective, open-label, dose-escalation study. Arthritis Rheum 64:908–913
Drewe E, Huggins ML, Morgan AG, Cassidy MJ, Powell RJ (2004) Treatment of renal amyloidosis with etanercept in tumour necrosis factor receptor-associated periodic syndrome. Rheumatology (Oxford) 43:1405–1408
Simsek I, Kaya A, Erdem H, Pay S, Yenicesu M, Dinc A (2010) No regression of renal amyloid mass despite remission of nephrotic syndrome in a patient with TRAPS following etanercept therapy. J Nephrol 23:119–123
Gattorno M, Pelagatti MA, Meini A, Obici L, Barcellona R, Federici S et al (2008) Persistent efficacy of anakinra in patients with tumor necrosis factor receptor-associated periodic syndrome. Arthritis Rheum 58:1516–1520
Jacobelli S, Andre M, Alexandra JF, Dode C, Papo T (2007) Failure of anti-TNF therapy in TNF receptor 1-associated periodic syndrome (TRAPS). Rheumatology (Oxford) 46:1211–1212
Nedjai B, Hitman GA, Quillinan N, Coughlan RJ, Church L, McDermott MF et al (2009) Proinflammatory action of the antiinflammatory drug infliximab in tumor necrosis factor receptor-associated periodic syndrome. Arthritis Rheum 60:619–625
Drewe E, Powell RJ, McDermott EM (2007) Comment on: Failure of anti-TNF therapy in TNF receptor 1-associated periodic syndrome (TRAPS). Rheumatology (Oxford) 46:1865–1866
Scallon B, Cai A, Solowski N, Rosenberg A, Song XY, Shealy D et al (2002) Binding and functional comparisons of two types of tumor necrosis factor antagonists. J Pharmacol Exp Ther 301:418–426
Vitale A, Rigante D, Lucherini OM, Caso F, Muscari I, Magnotti F et al (2013) Biological treatments: new weapons in the management of monogenic autoinflammatory disorders. Mediat Inflamm 2013:939847
Sacre K, Brihaye B, Lidove O, Papo T, Pocidalo MA, Cuisset L et al (2008) Dramatic improvement following interleukin 1beta blockade in tumor necrosis factor receptor-1-associated syndrome (TRAPS) resistant to anti-TNF-alpha therapy. J Rheumatol 35:357–358
Obici L, Meini A, Cattalini M, Chicca S, Galliani M, Donadei S et al (2011) Favourable and sustained response to anakinra in tumour necrosis factor receptor-associated periodic syndrome (TRAPS) with or without AA amyloidosis. Ann Rheum Dis 70:1511–1512
Quillinan N, Mannion G, Mohammad A, Coughlan R, Dickie LJ, McDermott MF et al (2011) Failure of sustained response to etanercept and refractoriness to anakinra in patients with T50M TNF-receptor-associated periodic syndrome. Ann Rheum Dis 70:1692–1693
Brizi MG, Galeazzi M, Lucherini OM, Cantarini L, Cimaz R (2012) Successful treatment of tumor necrosis factor receptor-associated periodic syndrome with canakinumab. Ann Intern Med 156:907–908
Arad U, Niv E, Caspi D, Elkayam O (2012) “TRAP” the diagnosis: a man with recurrent episodes of febrile peritonitis, not just familial Mediterranean fever. Isr Med Assoc J 14:229–231
Gattorno M, Obici L, Meini A, Tormey V, Abrams K, Davis N et al (2012) Efficacy and safety of canakinumab in patients with TNF receptor associated periodic syndrome [abstract]. Arthritis Rheum 64:749
Lopalco G, Rigante D, Vitale A, Frediani B, Iannone F, Cantarini L (2014) Tumor necrosis factor receptor-associated periodic syndrome managed with the couple canakinumab-alendronate. Clin Rheumatol Mar 11 - Epub ahead of print
Cantarini L, Vitale A, Magnotti F, Lucherini OM, Caso F, Frediani B et al (2013) Weekly oral alendronate in mevalonate kinase deficiency. Orphanet J Rare Dis 8:196
Nowlan ML, Drewe E, Bulsara H, Esposito N, Robins RA, Tighe PJ et al (2006) Systemic cytokine levels and the effects of etanercept in TNF receptor-associated periodic syndrome (TRAPS) involving a C33Y mutation in TNFRSF1A. Rheumatology (Oxford) 45:31–37
Vaitla PM, Radford PM, Tighe PJ, Powell RJ, McDermott EM, Todd I et al (2011) Role of interleukin-6 in a patient with tumor necrosis factor receptor-associated periodic syndrome: assessment of outcomes following treatment with the anti-interleukin-6 receptor monoclonal antibody tocilizumab. Arthritis Rheum 63:1151–1155
Conflict of interest
None
Author information
Authors and Affiliations
Corresponding author
Additional information
Donato Rigante and Giuseppe Lopalco have equally contributed to this manuscript.
Rights and permissions
About this article
Cite this article
Rigante, D., Lopalco, G., Vitale, A. et al. Key facts and hot spots on tumor necrosis factor receptor‐associated periodic syndrome. Clin Rheumatol 33, 1197–1207 (2014). https://doi.org/10.1007/s10067-014-2722-z
Received:
Revised:
Accepted:
Published:
Issue Date:
DOI: https://doi.org/10.1007/s10067-014-2722-z